Skip to main content
ORIGINAL RESEARCH

Long Acting Injectables and their Correlation with Subjectivity in Schizophrenia Spectrum Disorder

Psychopharmacology Bulletin 51(3): 27-37, 2021/06/01; https://doi.org/10.64719/pb.4407

Abstract

Nowadays, mental illness can no longer be considered as a mere list of symptoms corresponding to localized brain dysfunctions but rather as a disturbance of the patient’s subjectivity. Thus, a solid, qualitative study of patients’ subjectivity could represent a useful tool in the complex evaluation of efficacy of pharmacotherapy in schizophrenic persons. In this perspective, authors performed a phenomenological oriented investigation on 49 patients, diagnosed with schizophrenia spectrum disorder, who were receiving long-acting injectable (LAI) antipsychotic therapy. From data analysis, authors found a positive correlation between general psychopathology and the use of LAI antipsychotic therapies. The present study highlighted the necessity of a careful investigation of patients’ subjectivity in a phenomenological way as an irreducible part of both psychopathological and psychopharmacological matters.

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Ivano Caselli, Alessandra Gasparini, Marta Ielmini, Giulia Lucca, Stefano Amorosi, Nicola Poloni, Camilla Callegari. Long Acting Injectables and their Correlation with Subjectivity in Schizophrenia Spectrum Disorder. Psychopharmacology Bulletin. 2021/06/01; 51(3):27-37. https://doi.org/10.64719/pb.4407